GRANULES

Fundamental Analysis:

is a pharmaceutical manufacturer focused on APIs, pharmaceutical formulation intermediates, and finished dosages, with a strong presence in regulated global markets. In the latest quarter, the company reported 22.81% revenue growth and 33% net profit growth, reflecting improved operating performance and healthy demand momentum. FII holdings increased by 1.76%, indicating rising institutional confidence. Technical Analysis: The stock is in a strong uptrend and has recently broken out to fresh highs above the key resistance zone near ₹700, supported by sustained buying momentum. RSI near 78 indicates strong momentum though approaching overbought territory, while ADX above 37 signals a powerful ongoing trend. Sustaining above ₹720 can lead to further upside.